Programme

NICE and data analysis – what does the future hold?

The National Institute for Health and Care Excellence was established in 1999. It develops guidance for the National Health Service on a wide range of diseases and conditions, and provides advice on new drugs and medical technologies. Traditionally this guidance has been based on a review of the best available research evidence, on an economic analysis, and informed by input from experts and patients. Over the past 20 years, however, the availability of data – alongside research studies – has rapidly increased. Now some of our work is based on an analysis of real world data, such as for selected new cancer drugs. This data lets us see how the drugs work in practice, and the benefits they hold for patients. To build on this work, we have set up a new programme of work to routinely inform our guidance with analyses of relevant data. This will be particularly useful for answering questions where there is no published research, and to determine the effect of new interventions in day to day practice. We have set out our future plans for the use of data in a ‘Statement of intent’, which is currently the subject of consultation with key stakeholders and academics. The presentation will provide details of the future plans, reflecting on feedback from the consultation.


About the speaker
Prof Gillian Leng CBE

Gillian Leng is the Deputy Chief Executive at NICE and a visiting professor at King’s College London. Gillian trained in medicine at Leeds, and studied for an M.D. at Edinburgh University. She was involved in the Cochrane Collaboration as it became established, and still contributes as an editor. She worked as a consultant in public health medicine before moving to NICE in 2001. At NICE, Gillian led the set up of several major programmes, including the clinical guidelines programme, implementation, social care, quality standards and indicators and the NHS Evidence portal. Gillian chairs the national Shared Decision Making Collaborative and sits on several national boards. She is actively involved in research into quality improvement, and is a trustee at the Royal Society of Medicine, and chair of the Guidelines International Network.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more